Integrating genetic testing into management of all patients with amyotrophic lateral sclerosis: a critical juncture
Key points New evidence has led to a change in the way that some patients with amyotrophic lateral sclerosis (ALS) are classified and treated. Based on the findings of a landmark trial,[1][1] the drug tofersen was approved for the treatment of hereditary superoxide dismutase 1 ( SOD1 ) ALS by the
Authors
- Kerri Schellenberg
- Ari Breiner (ORCID: https://orcid.org/0000-0002-5225-3208)
- Christen L. Shoesmith (ORCID: https://orcid.org/0000-0003-2472-3804)
Institutions
- University of Ottawa (CA)
- Ottawa Hospital (CA)
Publication Details
- Journal
- Canadian Medical Association Journal
- Published
- 2025-09-21
- DOI
- https://doi.org/10.1503/cmaj.250257
- Citations
- 1
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63